All News

Autoimmune dz pts have higher risk of macular degeneration. Cleveland Clinic study of 200K AMD vs controls, finds: - SLE (RR 1.73) - Scleroderma (1.65) - Psoriasis (1.48) - Vasculitis (1.48) - RA (1.4) - UC &CD (~1.42) - Sarcoid (1.42) https://t.co/RrXaaqz3Aw https://t.co/9dGoGRCBYu

Links:

Dr. John Cush RheumNow ( View Tweet)
Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. You won’t want to miss it! https://t.co/86wJ323nwT https://t.co/WX1wBJ3yoo

Links:

Dr. John Cush RheumNow ( View Tweet)
pregnancy,embryo,fetal

Higher Rates of Childlessness in Rheumatic Diseases

d Jack Cush, MD

A large Finnish population study shows that several rheumatic diseases may impair reproduction and pregnancy outcomes, with significantly higher rates of childlessness or fewer children overall for women.

Read Article
High Mortality & complication rates seen in 53 #RA pts presenting w/ Periprosthetic joint infection - 54 PJI w/ avg age 65 yrs (32-88); mortality rate was 19%. Most common was Staphylococci (63%), w/ 20% w/ multiorganism infx & 6 C/S neg https://t.co/Syrm5qPKDQ https://t.co/bnMfMLmFJ7

Links:

Dr. John Cush RheumNow ( View Tweet)
BIOBADASER registry 1128 RA pts Rx w/ 1st ts/bDMARD, Among the 9.3% w. multimorbidity they noted higher DAS28 dz activity, but no differences in ts/bDMARD retention rates betw those w/ and without multimorbidity https://t.co/hZDpceuOFq https://t.co/pxSg6rKNNr

Links:

Dr. John Cush RheumNow ( View Tweet)
RA,polyarticular,black,rheumatoid

Secondary Sjogren’s Ups Rheumatoid Arthritis Severity

d Jack Cush, MD

A Swiss observational study has shown that rheumatoid arthritis (RA) patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.

Read Article
Marketing research suggests that the global rheumatoid arthritis drug market was valued at USD $17.87 billion in 2023 and is projected to reach around USD 25.67 billion by 2032 https://t.co/w4ErmjtFNV https://t.co/5bmcVJ7zh4

Links:

Dr. John Cush RheumNow ( View Tweet)
Chronic MSK Pain and Earlier Retirement Frequent musculoskeletal pain is linked with an increased risk of exiting work and retiring earlier, according to a new study published in the journal PLOS ONE. https://t.co/wRKYjmtaAX https://t.co/n5HzbDNmGz

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Naysayers & Disrupters (3.22.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week - including a few contrary reports on infection, seropositivity and plasmapheresis.

Read Article
We're gearing up for Tuesday Night Rheumatology all April long. Register today! Our first TNR takes place 4/2 at 6:30pm ET and will focus on Success in Rheumatoid Arthritis. https://t.co/FeeOdxOiRQ https://t.co/FNoCi6goQS

Links:

Dr. John Cush RheumNow ( View Tweet)
US Trends in RA DMARD Use 2017-2021 A trend analysis of disease-modifying anti-rheumatic drugs (DMARDs) shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. https://t.co/vQmVyAjIaL https://t.co/tSJ4H5XtnU

Links:

Dr. John Cush RheumNow ( View Tweet)
In RA, NO selective response with Seropositivity. Study of 28 eligible RCTs shows pts Rx w/ cs- or bDMARD that seropositivity did not predict better bDMARD response (ACR20 RRR ~1). Comparable resp in RF+ & RF- w/ TNFi or non-TNFi bDMARDs. https://t.co/AUWPgkzayt https://t.co/om9AYhNsQ9

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Review of DMARD Use in Rheumatoid Arthritis JAMA has reviewed the "2022 EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs". https://t.co/fpAigPpKzv https://t.co/GkbqW2BxpA

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Ides of March (3.15.2024)

d Jack Cush, MD

Dr. Jack Cush has advice for Caesar and the superstitious, and covers pregnancy, platelets, dialysis and vaccinations in Lupus.

Read Article
Again, a High Mortality with Depression and RA Last week we reported on a Korean study showing a 66% elevated mortality risk in RA patients with depression. This week, a new report shows depression in RA increases the mortality risk by more than 5 fold. https://t.co/C7Z7djny4S https://t.co/J9B6DUqcIC

Links:

Dr. John Cush RheumNow ( View Tweet)
DMARD,trends,2021

US Trends in RA DMARD Use 2017-2021

d Jack Cush, MD

A trend analysis of DMARDs shows that only half of rheumatoid arthritis (RA) patients are taking DMARDs, and that the COVID-19 pandemic substantially affected DMARD use. Despite numerous DMARD advances and evolving treatment guidelines since 1990, older therapies are still commonly used and the latest agents make up a small percentage of overall DMARD use.

Read Article
Dutch study of 586 RA pts on bDMARDs found more nonserious infections (NSIE) (77/100PYs) than serious infx (SIE)(1.3/100Pys). Upper respiratory tract infections were most frequent with recurrence rate that remained stable over time https://t.co/zwELL2yevG https://t.co/GLbidGvjp3

Links:

Dr. John Cush RheumNow ( View Tweet)
depression oh no HA

Again, a High Mortality with Depression and RA

d Jack Cush, MD

Last week we reported on a Korean study showing a 66% elevated mortality risk in RA patients (n=38,487) with depression.

Read Article
DANBIO #RA registry study: in 21,982 Rx starts (96K PtYrs) saw 1423 cancers w/ no overall increase in cancer risk with tocilizumab, sarilumab, abatacept, or rituximab (HRs from 0.7–1.1). No diff betw ABA vs TNFi (HR 1.41) nor HEME CA RTX vs TNFi (HR 0.09) https://t.co/mIEqALnnwI https://t.co/N1v3TzuBGm

Links:

Dr. John Cush RheumNow ( View Tweet)
Mixed Long-term Effects of Calcium and Vitamin D in Postmenopausal Women https://t.co/u2cf5hmTAE https://t.co/A4kdwG6eRm

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.